Industry Satellite Symposia

The Industry Satellite Symposium content and views expressed therein are those of the Exhibitors and not of ASTRO. Industry Satellite Symposia are held in conjunction with the 2021 Multidisciplinary Thoracic Cancers Symposium but the content is independent of the meeting. Dinner or other food and beverages may be provided by the companies, which may subject you to reporting under the Federal Sunshine Act (the Open Payments Program) or other state laws.

NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings

 

Wednesday, December 1, 2021
5:30 p.m. – 6:00 p.m.: Registration
6:00 p.m. – 8:00 p.m.: Symposium
Ironwood Meeting Room

Dinner will be provided.

Add to Calendar 12/01/2021 06:00 PM 12/01/2021 08:00 PM America/Phoenix NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings NSCLC Tumor Board: Multimodal Approaches to Optimize Immune Checkpoint Inhibition Strategies in Curative Settings
Wednesday, December 1, 2021 | 5:30 p.m. - 6:00 p.m MST: Registration | 6:00 p.m. - 8:00 p.m MST: Symposium
Ironwood Meeting Room
Dinner will be provided.

This activity is supported by an educational grant from Genentech Inc. and Merck & Co Inc.

Live, Interactive Virtual Streaming Available. Learn more!

View more information about the symposium.
Ironwood Meeting Room

This activity is supported by an educational grant from Genentech Inc. and Merck & Co Inc.

Live, Interactive Virtual Streaming Available. Learn more!

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the rationale for the application of immune checkpoint inhibitors into treatment plans for patients with early-stage and locally advanced, unresectable NSCLC
  • Assess efficacy and safety profiles of immune checkpoint blockade evaluated in patients with unresectable stage III NSCLC, and resectable stage I-III NSCLC
  • Develop proactive strategies to identify and mitigate toxicities associated with immunotherapy-based regimens among patients with stage I-III NSCLC
  • Translate evidence-based guidelines and updated data on immune checkpoint inhibitors in stage I-III NSCLC into personalized treatment plans, with a focus on improving collaboration and role harmonization between thoracic surgeons, radiation oncologists and medical oncologists

Accreditation Statement

PER is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. It is estimated that 2.0 AMA PRA Category 1 Credits™ will be made available for the live virtual initiative and endured recording and 1.5 AMA PRA Category 1 Credits™ will be made available for the online Community Practice Connections® initiative. Final determination of credits will be based upon final agenda.

The 2021 Multidisciplinary Thoracic Cancers Symposium Steering Committee has reviewed and approved this symposium as appropriate for presentation as an Industry Satellite Symposium (ISS). The ISS constitutes the content and views of the sponsor and is not part of the official 2021 Multidisciplinary Thoracic Cancers Symposium program.

Co-Sponsors

American Society for Radiation Oncology
251 18th Street South, 8th Floor
Arlington, VA 22202
Telephone: 703-502-1550
www.astro.org

TERMS OF USE & PRIVACY POLICY

Connect With Us: